Philipp Wendel

In-depth comparative characterization identifies scalable CD123-CAR-NK cells as promising strategy to combat AML

Evelyn Ullrich, Fenja Gierschek, Lea Kramer, Christina Kühn et autres

de, gb, cn (code pays fourni par la source)

Menin-Inhibition Sensitizes Acute Myeloid Leukemia to CLEC12A-Directed CAR Cell Therapy

Johanna Rausch, Philipp Wendel, Margarita M. Dzama, Marlene Steiner et autres

Abstract Menin inhibitors targeting the Menin-KMT2A chromatin complex have emerged as highly selective therapies for KMT2A -rearranged ( KMT2A -r) and NPM1 -mutated ( NPM1 mut ) acute myeloid leukemia (AML), with recent regulatory approval and increasing interest in combination strategies. In …

de (code pays fourni par la source)

Biological Classification of Natural Killer and Innate Lymphoid Cells

Fenja Gierschek, Melinda Baulig, Daniel Hartmann, Philipp Wendel et autres

de (code pays fourni par la source)

Fura-10, unlike fura-2, is suitable for long-term calcium imaging in natural killer (NK) cells without compromising cytotoxicity and can be combined with target cell death analysis

Lea Kaschek, Joanne Vialle, Gebhard Stopper, Markus D. A. Hoffmann et autres

• Fura-10 does not compromise NK cell cytotoxicity against cancer cells • Fura-2 may compromise NK cell cytotoxicity against cancer cells • Fura-10 is bright, has a good signal-to-noise ratio, shows little bleaching/leaking • Fura-10 works well in primary human NK cells …

de (code pays fourni par la source)

Menin-inhibition boosts CAR-T cell therapy against NPM1 mutated and KMT2A-rearranged acute myeloid leukemia

Johanna Rausch, Philipp Wendel, Viktor Fetsch, Marie Kuhmann et autres

Abstract Inhibitors disrupting the Menin-KMT2A chromatin complex have emerged as an auspicious treatment for KMT2A-rearranged (KMT2A-r) leukemias. We previously discovered that NPM1-mutated (NPM1m) AML has a similar dependency on the interaction of menin with wild-type KMT2A and that menin inhibitors (men-i) suppress …

de (code pays fourni par la source)

In vitro and in vivo comparison of VHH- and scFv-based CLEC12A-chimeric antigen receptor-natural killer cells against acute myeloid leukemia

Fenja Gierschek, Philipp Wendel, Jan Habermann, Lynne Knapp et autres

Treatment of acute myeloid leukemia (AML) remains challenging due to its heterogeneity and lack of suitable target antigens. CLEC12A (CLL-1), expressed on leukemic blasts and leukemia-initiating cells in up to 92% of AML patients, offers an attractive target for CAR-based immune cell …

de (code pays fourni par la source)

Migration Dynamics of Human NK Cell Preparations in Microchannels and Their Invasion Into Patient‐Derived Tissue

Alina Moter, Sonja Scharf, Hendrik Schäfer, Tobias Bexte et autres

Natural killer (NK) cells are characterised by their ability to attack cancer cells without prior antigen stimulation. Additionally, clinical trials revealed great potential of NK cells expressing chimeric antigen receptors (CARs). Successful anti-tumour efficacy remains limited by migration and infiltration to the …

de, fr (code pays fourni par la source)

CAR-CIK vs. CAR-T: benchmarking novel cytokine-induced killer cells as solid tumor immunotherapy in ErbB2+ rhabdomyosarcoma

Laura M. Moser, Catrin Heim, Sebastian E. Koschade, Philipp Wendel et autres

Introduction CAR-T cell therapy, though successful in hematologic malignancies, faces challenges in solid tumors due to limitations of autologous T cells. Cytokine-induced killer (CIK) cells can be given safely across allogeneic barriers and constitute alternative effector cells generated from healthy donors. CIK …

de, us (code pays fourni par la source)

Fura-10, unlike fura-2, is suitable for long-term calcium imaging in natural killer (NK) cells without compromising cytotoxicity and can be combined with target cell death analysis

Lea Kaschek, Joanne Vialle, Gebhard Stopper, Markus D. A. Hoffmann et autres

CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cells

Tobias Bexte, Nawid Albinger, Ahmad Al Ajami, Philipp Wendel et autres

Abstract Chimeric antigen receptor (CAR)-modified natural killer (NK) cells show antileukemic activity against acute myeloid leukemia (AML) in vivo. However, NK cell-mediated tumor killing is often impaired by the interaction between human leukocyte antigen (HLA)-E and the inhibitory receptor, NKG2A. Here, we …

de, Égypte (code pays fourni par la source)

CD16+ as predictive marker for early relapse in aggressive B-NHL/DLBCL patients

Sylvia Zöphel, Nadja Küchler, Johanna Jansky, Cora Hoxha et autres

Assessing the prognosis of patients with aggressive non-Hodgkin B cell lymphoma mainly relies on a clinical risk score (IPI). Standard first-line therapies are based on a chemo-immunotherapy with rituximab, which mediates CD16-dependent antibody-dependent cellular cytotoxicity (ADCC). We phenotypically and functionally analyzed blood …

de, nl (code pays fourni par la source)

T cell receptor-directed antibody-drug conjugates for the treatment of T cell-derived cancers

Katrin Schoenfeld, Jan Habermann, Philipp Wendel, Julia Harwardt et autres

T cell-derived cancers are hallmarked by heterogeneity, aggressiveness, and poor clinical outcomes. Available targeted therapies are severely limited due to a lack of target antigens that allow discrimination of malignant from healthy T cells. Here, we report a novel approach for the …

de (code pays fourni par la source)